Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Shares Outstanding (Weighted Average) (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 317.9% to $2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 317.9% increase, with the full-year FY2024 number at $697686.0, up 362.24% from a year prior.
  • Shares Outstanding (Weighted Average) was $2.2 million for Q3 2025 at Ensysce Biosciences, up from $1.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $15.9 million in Q2 2021 to a low of $113696.0 in Q1 2022.
  • A 5-year average of $2.5 million and a median of $1.0 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 99.28% in 2022, then soared 1445.21% in 2023.
  • Ensysce Biosciences' Shares Outstanding (Weighted Average) stood at $1.0 million in 2021, then plummeted by 82.15% to $179925.0 in 2022, then fell by 16.11% to $150937.0 in 2023, then soared by 362.24% to $697686.0 in 2024, then surged by 210.78% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Shares Outstanding (Weighted Average) are $2.2 million (Q3 2025), $1.8 million (Q2 2025), and $1.4 million (Q1 2025).